Jörg H.
- Country
- Germany
- Department
- Klinik für Hämatologie/Onkologie/Immunologie
Research Overview
- Efficacy of Venetoclax and Azacitidine Versus Standard Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with NPM1 Mutations
- Evaluation of Tolerability and Efficacy of Asciminib Hydrochloride Versus Nilotinib in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
- Phase I/II Study of Venetoclax, Cytarabine, and Mitoxantrone in Relapsed or Refractory Acute Myeloid Leukemia Eligible for Intensive Salvage Therapy
Data & Insights
Has run more than one trial at 65 of 225 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in treating various forms of acute and chronic leukemia, with particular focus on Philadelphia-Chromosome positive acute lymphoblastic leukemia and chronic myeloid leukemia.
- Acute Myeloid Leukemia (AML) Therapeutics
- Multiple Myeloma Treatment
- BCR-ABL1 Targeted Therapies
The investigator explores innovative treatment approaches combining conventional chemotherapy with targeted molecular therapies.
Stem Cell Transplantation
Expertise in both allogeneic and autologous stem cell transplantation procedures, particularly focusing on their application in relapsed and refractory disease settings.
- Graft-versus-Host Disease Management
- Salvage Therapy Protocols
- Conditioning Regimen Optimization
Advanced experience in transplantation strategies for various hematologic conditions including germ cell tumors.
Novel Therapeutic Approaches
Development and implementation of targeted molecular therapies and immunotherapy protocols for hematologic malignancies.
- Tyrosine Kinase Inhibitor Therapy
- Venetoclax-Based Combinations
- Treatment Discontinuation Strategies
Focus on developing personalized treatment approaches for patients with various blood cancers and related disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.